# OnCo record idea-post-neoadjuvant-adc (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-post-neoadjuvant-adc/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-post-neoadjuvant-adc" ;
  schema:name "ADC for residual disease after KEYNOTE-522"@en ;
  schema:description "Patients whose TNBC survives chemo-immunotherapy before surgery have a high relapse risk. Give them an ADC after surgery."@en ;
  schema:url <https://onco.cc/ideas/idea-post-neoadjuvant-adc/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03036488> ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:terms <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/pcr/> ;
  onco:trials <https://onco.cc/trials/keynote-522/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-522-n-engl-j-med-2020/>, <https://onco.cc/key-papers/paper-keynote-355-lancet-2020/>, <https://onco.cc/key-papers/paper-ascent-nejm-2021/> .